Peptide Marriages: Modular Assembly of Multi-Agonist Therapeutics.
Multi-agonist peptide research just got a serious upgrade. The Cambridge-based team behind "Peptide Marriages" has built a modular system that lets researchers snap together different peptide agonists on a single scaffold—like biotech LEGO for multi-agonist therapeutics.
Chemistry
by Kostadinova KA, Venne JL, Krajcovicova S et al.
“Peptide Marriages: Modular Assembly of Multi-Agonist Therapeutics. Kostadinova KA(1), Venne JL(1), Krajcovicova S(1)(2), Dodgson J(3), Hogendorf WFJ(4), Nielsen TE(4), Hymel D(5), Bolt H(3)(6), Collinson A(3), Day J(7), Revell J(3)(6), Spring DR(1). Author information: (1)Yusuf Hamied Department of Chemistry, University of Cambridge, Cambridge, UK. (2)Department of Organic Chemistry, Faculty of Science, Palacky University Olomouc, Olomouc, Czech Republic. (3)Biologics Engineering, Oncology R&D, AstraZeneca, Cambridge, UK. (4)Therapeutics Discovery, Novo Nordisk A/S, Måløv, Denmark. (5)Novo Nordisk US R&D, Lexington, Massachusetts, USA. (6)Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK. (7)Department of Earth Sciences, University of Cambridge, Cambridge, UK. Multi-receptor peptide agonists represent an effective strategy for obesity treatment, extending the success of incretin-based therapies through simultaneous engagement of complementary targets. Their development, however, is synthetically demanding, as each receptor combination typically requires de novo preparation of large fusion peptides. We report a modular polyethylene glycol (PEG)-based scaffold that enables orthogonal attachment of up to three functional components, including therapeutic peptides, half-life-extending units, and other labels, via sequential strain-promoted azide-alkyne cycloaddition (SPAAC) and copper-catalysed azide-alkyne cycloaddition (CuAAC). The scaffold is assembled on solid phase without intermediate purification, providing a readily accessible and versatile linker. Using glucagon-like peptide-1 (GLP-1) and amylin receptor agonists as a proof-of-concept, dual-agonist constructs with tuneable valency and functionality were rapidly generated. Lead conjugates displayed balanced, low-picomolar potency at both receptors in cyclic adenosine monophosphate (cAMP) assays and showed selective receptor-mediated internalisation in GLP-1 receptor-expressing cells. This orthogonal click-based platform enables rapid and modular multi-agonist assembly, facilitating systematic exploration of receptor combinations, valency, and payload effects. Beyond incretin biology, it offers a general route to multifunctional peptide therapeutics and diagnostics. © 2026 The Author(s). Chemistry – A European Journal published by Wiley‐VCH GmbH.”
Here’s the deal: Multi-receptor peptide agonists tackle tough targets (think obesity, diabetes) by hitting more than one receptor at once. But the chemistry is a headache. Each new combo usually means designing and synthesizing a giant fusion peptide from scratch. Not exactly plug-and-play.
This new approach flips the script. The researchers developed a polyethylene glycol (PEG)-based scaffold with three attachment points. Each spot can be loaded with a therapeutic peptide, a half-life extender, or a label, using click chemistry. No need for intermediate purifications. No endless custom syntheses. It’s a clean, fast way to mix and match components.
Key points:
The scaffold uses strain-promoted and copper-catalyzed azide-alkyne cycloaddition for orthogonal, sequential loading.
Solid-phase assembly—no stopping for purification between steps.
Dual-agonist constructs (like GLP-1 and amylin) were built quickly and showed potent, balanced activation at both targets.
This is more than a trick for obesity research. The platform can generate any multi-functional peptide combo, for therapeutics or diagnostics.
For peptide researchers looking to build custom multi-agonists or explore new receptor combinations, this is a big deal. The toolkit opens up rapid, systematic exploration—no more waiting months for a single fusion peptide.
Explore more on the technical side of peptide synthesis at our peptide research index. If you need sourcing options for research compounds, check our vendor directory.
Modular peptide assembly just made multi-agonist research a lot more accessible.
Related Reading
The STRIDE Trial and Semaglutide: Implications for Clinical Vascular Practice.
News · J Med ChemStructure-Based Adaptation of a SARS-CoV-2 Neutralizing Peptide to New Virus Variants.
News · J Nucl MedCombining an α(v)β(6)-Targeted (177)Lu-Based Peptide Receptor Radionuclide Therapy with Olaparib to Boost Therapeutic Efficacy in Pancreatic Cancer.
For Research Use Only
All content published on Pushing Peptides is intended for educational and informational purposes only. The information provided is not intended as medical advice, diagnosis, or treatment. Peptides discussed in this article are research compounds and are not approved for human therapeutic use by the FDA or any other regulatory agency. All studies referenced involve animal models or in vitro research unless otherwise stated. Consult a qualified healthcare professional before making any decisions related to your health. Pushing Peptides does not sell peptides — we are a vendor directory and educational resource.